SlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025HCV Micro-Elimination Approaches: IV Drug Users – Spilios ManolakopoulosView Slideset
PKPavel KhaykinMDVideoViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025HCV Elimination: Why Do We Still Have Gaps and How Do We Close These Gaps? - Pavel KhaykinView Video
PKPavel KhaykinMDSlidesetViral Hepatitis and Liver Disease23rd European Meeting on HIV & Hepatitis 2025HCV Elimination: Why Do We Still Have Gaps and How Do We Close These Gaps? - Pavel KhaykinView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #17 Clonal Analysis of Near Full-Length Proviral HIV-1 Genome Enables Differentiation of APOBEC- and Drug-Resistant Populations in Highly Treatment Experienced People Living with HIV - Martin DäumerView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #17 Clonal Analysis of Near Full-Length Proviral HIV-1 Genome Enables Differentiation of APOBEC- and Drug-Resistant Populations in Highly Treatment Experienced People Living with HIV - Martin DäumerView Slideset
FGFederico GarcíaPharmD, PhDSlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #16 APOBEC-Associated Mutations in HIV Drug Resistance: Challenges in Interpretation Using Next-Generation Sequencing - Federico GarcíaView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #15 Virologic Failure and Resistance Emergence During Treatment with B/F/TAF or DTG/3TC in PWH Without Prior Resistance Mutations: A Real-World Study - Thomas DrumelView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #15 Virologic Failure and Resistance Emergence During Treatment with B/F/TAF or DTG/3TC in PWH Without Prior Resistance Mutations: A Real-World Study - Thomas DrumelView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #14 Three-Years Outcome After Genotyping-Guided Switch in HIV Multi-Drug Resistant Patients in Cameroon: Evidence-Based Strategies for Achieving Epidemic Control in Low-and Middle-Income Countries - Ezechiel Ngoufack Jagni SemengueView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #14 Three-Years Outcome After Genotyping-Guided Switch in HIV Multi-Drug Resistant Patients in Cameroon: Evidence-Based Strategies for Achieving Epidemic Control in Low-and Middle-Income Countries - Ezechiel Ngoufack Jagni SemengueView Slideset
VideoHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #13 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes - Mafalda N.S. MirandaView Video
SlidesetHIV23rd European Meeting on HIV & Hepatitis 2025Abstract #13 Estimating the Genetic Barrier for Resistance to Integrase Inhibitors for the Most Frequently Circulating HIV-1 Subtypes - Mafalda N.S. MirandaView Slideset
